Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALICE: Atezolizumab plus immunogenic chemotherapy in metastatic triple-negative breast cancer
2016-003570-40Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in triple-negative breast cancer (TNBC) comparing Tecentriq + Caelyx + Sendoxan with Placebo + Caelyx + Sendoxan (2 arms). Primary endpoint: Progression-free survival (PFS). Started May 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2016-003570-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003570-40.